

## 7<sup>th</sup> International CCS Workshop

May 12<sup>th</sup>, 2022

Online - Meeting



## 17<sup>th</sup> International CLL Workshop

May 13-14<sup>th</sup>, 2022

Online - Meeting

### Update on Biology and Therapy of Chronic Lymphocytic Leukemia

The Cancer Cluster Salzburg (CCS) meeting will be held jointly with our annual workshop on chronic lymphocytic leukemia "Update on Biology and Therapy of Chronic Lymphocytic Leukemia (CLL)" and provides a stimulating forum to share and discuss exciting and novel data. Both workshops will be held on **May 12<sup>th</sup> – May 14<sup>nd</sup> 2022** as a virtual online Meeting. The conference will provide an update on the most recent insights into basic and clinical aspects of cancer.

We are confident that this workshop with a very ambitious scientific program will be most memorable to you.

Please register via our homepage:

<https://www.cancercluster-salzburg.at/ccs-cll-conference>

#### **Workshop Venue:**

Virtual Meeting/online

Access information will be provided in time after the registration

# Scientific Program

## Cancer Cluster Salzburg Workshop

**Day 1: May 12<sup>th</sup> 2022; 9.30 – 15.15 (Central European Summertime)**

**9.30 – 9.40**

Welcome and Introduction

Richard Greil and Fritz Aberger (Salzburg, Austria)

### **Session I: Oncoimmunology**

Chair: Richard Greil (Salzburg, Austria)

**9.40 – 10.10**

*“Inflammasomes in Myeloid Malignancies”*

Jutta Horejs-Höck (Salzburg, Austria)

**10.10 – 10.40**

*“Novel treatment options in blast phase chronic myeloid leukaemia”*

Mhairi Copland (Glasgow, UK)

**10.40 – 11.10**

*“Molecular control of paracrine signals in the tumour micro-environment”*

Dirk Schmidt-Arras (Salzburg, Austria)

**11.10 – 11.25**

**Meet & discuss in the CCS Lounge**

**11.25 – 12.30 Lunch Break**

### **CCS Keynote Lecture**

Chair: Fritz Aberger (Salzburg, Austria)

**12.30 – 13.30**

*““Bacterial sabotage” drives castration resistant prostate cancer”*

Andrea Alimonti (ETH Zürich, Switzerland)

### **Session II: Cancer Genetics**

Chair: Fritz Aberger (Salzburg, Austria)

**13.30 – 14.00**

*“Metabolic rewiring driving metastasis formation”*

Sarah-Maria Fendt (Leuven, Belgium)

**14.00 – 14.30**

*“tba”*

Jason Moffat (Toronto, Canada)

**14.30 – 15.00**

*“Single-cell Multi-omics Profiling of the Heterogeneous Tumor micro-environment”*

Diether Lambrechts (Leuven, Belgium)

**15.00 – 15.15**

**Meet & discuss in the CCS Lounge**

# Scientific Program

## Chronic Lymphocytic Leukemia Workshop

**Day 2: May 13<sup>st</sup> 2022; 10.15 – 15.45 (Central European Summertime)**

**10.15 – 10.30**

Welcome and Introduction  
Richard Greil (Salzburg, Austria)

### **Session I: CLL Microenvironment**

Chair: Nadja Zaborsky (Salzburg, Austria)

**10.30 – 11.00**

*“Notch-signalling facilitates immune escape in CLL and MCL”*  
Ingo Ringshausen (Cambridge, UK)

**11.00 – 11.30**

*“Development of CAR-T cells simultaneously targeting B cell malignancies and the tumor-supportive microenvironment”*  
Uta Höpken (Berlin, Germany)

**11.30 – 12.00**

*“Metabolic reprogramming in the CLL microenvironment; new therapeutic vulnerabilities”*  
Eric F. Eldering (Amsterdam, Netherlands)

**12.00 – 12.15**

**Meet & discuss in the CLL Lounge**

**12.15 – 13.00 Lunch Break**

### **CLL Keynote Lecture**

Chair: Alexander Egle (Salzburg, Austria)

**13.00 – 14.00**

*“CLL genomics: Mapping disease heterogeneity and transformation”*  
Catherine Wu (Dana-Farber Cancer Institute, Boston, MA, USA)

### **Session II: CLL Genetics**

Chair: Roland Geisberger (Salzburg, Austria)

**14.00 – 14.30**

*„A gene expression signature of Endothelial-Mesenchymal-Transition defines a large subgroup of CLL patients with higher genomic stability”*  
Daniel Mertens (Heidelberg, Germany)

**14.30 – 15.00**

*“Immunogenetic insight into the natural history of CLL”*  
Kostas Stamatopoulos (Thessaloniki, Greece)

**15.00 – 15.30**

*“Role of Activation Induced Cytidine Deaminase (AID) in CLL progression”*  
Pablo Opezzo (Montevideo, Uruguay)

**15.30 – 15.45**

**Meet & discuss in the CLL Lounge**

**Day 3: May 14<sup>th</sup> 2022; 9.00 – 11.00 (Central European Summertime)**

**Session III: Clinical aspects of CLL**

Chair: Richard Greil

**9.00 – 9.30**

*“Frontline treatment-strategies for non-p53 deficient CLL: limited vs. indefinite treatments”*

Constantine S. Tam (Melbourne, Australia)

**9.30 – 10.00**

*“Higher Risk CLL (mostly p53 deficient) therapy planning – are there limited treatment duration options”*

Clemens Wendtner (Munich, Germany)

**10.00 – 10.30**

*“In a world without OS Benefit: Is there still a role for short Chemotherapy approaches in initial treatment or is chemo dead?”*

Tahla Munir (Leeds, UK)

**10.30 – 10.45**

Closing remarks: Richard Greil (Salzburg, Austria)

**10.45 – 11.00**

**Meet & discuss in the CLL Lounge**



Salzburg  
Cancer  
Research  
Institute

**LIMCR**  
Laboratory for  
Immunological and  
Molecular Cancer Research



UNIVERSITÄTSKLINIK FÜR  
**INNERE MEDIZIN III**

Organisation Institution:

SCRI-LIMCR gemeinnützige GmbH  
Müllner Hauptstraße 48  
5020 Salzburg  
Austria

Scientific Organising Committee:

Univ. Prof. Dr. Richard Greil, Salzburg

Dr. Nadja Zaborsky, Salzburg

PD. Dr. Roland Geisberger, Salzburg

ao. Univ. Prof. Dr. Alexander Egle, Salzburg

*Laboratory for Immunological and Molecular Cancer Research*

*Third Medical Department with*

*Hematology, Oncology, Hemostaseology, Infectiology and*

*Rheumatology, Paracelsus Medical University, Salzburg, Austria*

Prof. Dr. Fritz Aberger

*Department Biosciences, Paris-Lodron University Salzburg*

Contact: <https://www.cancercluster-salzburg.at/ccs-cll-conference>

KINDLY SUPPORTED BY:

(Alphabetical order)

abbvie

AstraZeneca 

Celgene |  Bristol Myers Squibb<sup>TM</sup>  
Company

janssen   
PHARMACEUTICAL COMPANIES  
OF *Johnson & Johnson*

 NOVARTIS

 Roche